Oct 8, 2017
MediSieve Team Welcomes a New Product Engineer
MediSieve has recently welcomed William Twigger (ex Baxter and First Water) as their new Product Engineer
LONDON – October 08, 2017 – MediSieve, an award-winning start-up that manufactures a revolutionary life-saving blood filtration device, has recently welcomed William Twigger as their new Product Engineer.
Joining the three-person Product Development team at an exciting time of development, Twigger is poised to bring his wealth of experience to furthering the innovation of MediSieve by taking responsibility for the engineering aspects of MediSieve’s product development.
Graduating with a BA honours in Metallurgy and Material Science in 2010 from the University of Birmingham, Twigger went on to have a successful career in the medical product engineering sector.
George Frodsham, CEO of MediSieve, commented on Twigger’s recent appointment: "It’s really great to have Will working with us, and it’s another exciting development for the company, which is rapidly growing."
"William brings a wealth of engineering knowledge to the company and we’re all delighted to welcome him to the team."
As the Design Control Engineer at Baxter, ApaTech, from 2016 to 2017, Twigger was an instrumental part of the company’s product manufacturing and engineering design. Developing class three medical devices, which are used to substitute bone as part of surgical procedures, the company is integral to the success of a number of procedures, such as hip replacements.
Before his tenure at Baxter, ApaTech, Twigger was First Water’s Senior Development Engineer. A successful biomaterials company, First Water have a focus on the research, development and manufacture of wound care products used to treat chronic skin conditions. Twigger was directly responsible for updating key documents, such as user requirements, risk files, design inputs and traceability matrices, in order to remediate before an FDA audit.
Of his new appointment, Twigger said, "I’m incredibly excited to be joining such an exciting start-up, and to be working with such a great team."
"It’s a great opportunity for me and I’m confident that my experience will help drive continued innovation at the company."
MediSieve is developing a revolutionary device used to magnetically filter blood. Similar to dialysis, the patient’s blood is circulated through an external loop in order to remove any disease-causing particles or cells. Unlike dialysis, MediSieve uses antibody-coated magnetic particles to target and remove specific components, providing a flexible, adaptable platform technology to enable new treatments for a wide range of different diseases.
MediSieve can be used alongside drug therapy treatments in the treatment of malaria, leukaemia and sepsis, removing different specific targets in each case, such as pathogens, malaria-infected cells or circulating leukaemia cells.
Progressing to clinical trials in 2018, the MediSieve team is constantly working on ways to broaden the application of the device and research is ongoing.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
